Atypical haemolytic uraemic syndrome (aHUS) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051103
Expand allThis document outlines details of PBS-subsidised eculizumab and ravulizumab for patients with atypical haemolytic uraemic syndrome (aHUS).
aHUS and listing dates
aHUS is a rare and life-threatening immune condition that causes abnormal blood clots to form in small blood vessels in the kidneys.
Listing dates:
See Written Authority Required Drugs for more information.
Enquiries
Transfer enquiries about prescription arrangements to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated.
The Resources page contains:
- application forms
- calculation sheets
- contact details
- FAQs from Service Officers
- restriction and item codes
- the PBS schedule
- Services Australia website link
Related links
Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)
Processing and National Demand Allocation (PaNDA)
Processing Complex Authority Required Listings
Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)
Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)
Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)
Tier 0 technical support - self-sufficiency
Tier 1 technical support - Local Peer Support (LPS)
Written Authority Required Drugs